PharmaEssentia has secured a significant regulatory milestone as the FDA approved a label expansion for its rare blood cancer drug Besremi, known generically as ropeginterferon alfa-2b-njft.
The drug, first approved by the FDA in 2021 for polycythemia vera, has now gained clearance to treat adults with essential thrombocythemia, a separate rare blood disorder.
The FDA had set an August 30, 2026 PDUFA decision date for the supplemental biologics license application targeting the essential thrombocythemia indication.
Essential thrombocythemia is a rare and chronic condition in which the bone marrow produces too many platelets, increasing the risk of clotting and serious cardiovascular complications.
Besremi is now recognised as the first new therapy approved for essential thrombocythemia in nearly 30 years, marking a substantial shift in the treatment landscape for patients with the condition.
The approval was supported by data from the SURPASS-ET phase 3 clinical trial, which evaluated Besremi as a second-line therapy measured against the platelet-reducing drug anagrelide.
Results from the trial showed that 42.9% of patients treated with Besremi achieved durable responses at months 9 and 12, a striking result compared with the anagrelide arm.
In the anagrelide arm of the same trial, just 6% of patients achieved a comparable durable response at those same time points, underlining the clinical significance of the Besremi data.
PharmaEssentia had been preparing ahead of the anticipated decision, positioning itself for a potential launch into what would represent a new and considerably larger US market.
The essential thrombocythemia patient population is broader than polycythemia vera, meaning the label expansion could meaningfully increase the commercial reach of Besremi across the United States.
The approval represents a defining moment for PharmaEssentia as it looks to build on its position in the rare haematological cancer space with a drug that now spans two distinct indications.
With a strong clinical data package behind it and a decades-long gap in therapeutic innovation now addressed, Besremi is set to become a more central treatment option for haematologists managing patients with rare blood cancers.